According to TipRanks.com, Valiquette is a 2-star analyst with an average return of 0.3% and a 52.7% success rate. Valiquette covers the Healthcare sector, focusing on stocks such as Solventum ...

As of March 6 at 2:46:58 PM EST. Market Open.

In addition to Stifel Nicolaus, Zymeworks also received a Buy from LifeSci Capital’s Charles Zhu in a report issued yesterday. However, on the same day, TipRanks – OpenAI reiterated a Hold rating on ...

Zymeworks Inc. is rated a Buy with improved FY25 profitability, narrowed net loss by 34%, and strong liquidity with $270.6M. Read more on ZYME stock here.

Nasdaq Official Closing Price (NOCP)" is a process for identifying the Nasdaq market-specific closing price for Nasdaq-listed issues. Data provided by Nasdaq Data Link, a premier source for financial, ...

XCells Biotechnologies USA, Inc. requests that their press release NewsItemId: 20260311932205 issued March 11, 2026 "iXCells Biotechnologies Reaches iPSC Line Delivery Milestone in Collaboration With ...

Zymeworks (ZYME) delivered earnings and revenue surprises of -58.64% and -88.23%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is ...

Zymeworks Inc. Annual cash flow by MarketWatch. View ZYME net cash flow, operating cash flow, operating expenses and cash dividends.

Zymeworks to receive $250 million under a royalty-backed note financing from Royalty Pharma with repayments due from 30% of ...

Q4 2025 earnings call: zanidatamab Phase III update, FDA timeline, $250M royalty-note financing, milestones, cash runway & ...